Use of inflammatory markers to guide cancer treatment

Clarke, S.J., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles, K. and McMillan, D.C. (2011) Use of inflammatory markers to guide cancer treatment. Clinical Pharmacology and Therapeutics, 90(3), pp. 475-478. (doi:10.1038/clpt.2011.122)

Full text not currently available from Enlighten.

Abstract

Patient-related factors, especially markers of inflammatory response, are prognostic in many common solid cancers. Here we review how such markers, in particular the acute-phase proteins C-reactive protein and albumin and a differential white cell count, can predict treatment outcomes in cancer patients. The review examines the literature pertaining to surgery, chemotherapy, and radiotherapy and discusses how inflammatory markers might be incorporated into the planning and monitoring of cancer treatments.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMillan, Professor Donald
Authors: Clarke, S.J., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles, K., and McMillan, D.C.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing > Clinical Specialities
Journal Name:Clinical Pharmacology and Therapeutics
ISSN:0009-9236
Published Online:20 July 2011

University Staff: Request a correction | Enlighten Editors: Update this record